Stock Traders Purchase Large Volume of Reviva Pharmaceuticals Call Options (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) saw unusually large options trading on Tuesday. Traders acquired 13,196 call options on the stock. This represents an increase of approximately 374% compared to the average daily volume of 2,782 call options.

Reviva Pharmaceuticals Stock Up 13.0 %

Shares of NASDAQ RVPH traded up $0.23 during mid-day trading on Tuesday, reaching $2.00. 3,874,227 shares of the company were exchanged, compared to its average volume of 3,016,689. Reviva Pharmaceuticals has a 52 week low of $0.60 and a 52 week high of $4.83. The company's 50 day moving average price is $1.67 and its 200 day moving average price is $1.32. The stock has a market capitalization of $66.88 million, a PE ratio of -1.80 and a beta of -0.12.

Institutional Investors Weigh In On Reviva Pharmaceuticals

A hedge fund recently raised its stake in Reviva Pharmaceuticals stock. Geode Capital Management LLC increased its holdings in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) by 17.9% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 278,496 shares of the company's stock after purchasing an additional 42,376 shares during the quarter. Geode Capital Management LLC owned 0.83% of Reviva Pharmaceuticals worth $401,000 as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 63.18% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on RVPH shares. EF Hutton Acquisition Co. I raised shares of Reviva Pharmaceuticals to a "strong-buy" rating in a research report on Monday, September 23rd. Maxim Group raised Reviva Pharmaceuticals from a "hold" rating to a "buy" rating and set a $7.00 price target for the company in a report on Friday, January 10th. D. Boral Capital reiterated a "buy" rating and set a $15.00 price objective on shares of Reviva Pharmaceuticals in a research note on Tuesday. Roth Capital raised Reviva Pharmaceuticals to a "strong-buy" rating in a report on Friday, January 10th. Finally, Roth Mkm started coverage on shares of Reviva Pharmaceuticals in a research note on Friday, January 10th. They issued a "buy" rating and a $7.00 target price on the stock. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of "Buy" and an average target price of $12.00.

Reviva Pharmaceuticals Company Profile

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.